The effect of valsartan on oxidative stress in type 2 diabetic patients with hypertension: prospective, randomized, open label, active control, multi-center study

The effects of valsartan on oxidative stress in type 2 diabetic patients with hypertension

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0001498

Enrollment

Registered

2015-05-20

Start date

2009-08-27

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : vasartan vs. amlodipine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 DM patients systolic BP (SBP) 135 – 160 mmHg and/or diastolic BP (DBP) 85 – 100 mmHg, 30 - 80 years of age, not taking antihypertensive drugs within 2 weeks prior to screening date HbA1c =9.0%.

Exclusion criteria

Exclusion criteria: secondary hypertension, impaired hepatic function (defined by serum levels of either ALT or AST >2.5 times the upper limit of normal), renal impairment (serum creatinine >2.0 mg/dL)), or any other clinically relevant serious disease, including malignancy, serious infection, heart failure, myocardial infarction or stroke within 6 months prior to the screening date, or patients who were pregnant, breast-feeding, or planning to bear a child, or whose low-density lipoprotein cholesterol (LDL-C) >160 mg/dL

Design outcomes

Primary

Measure	Time frame
oxidative stress marker	—

Secondary

Measure	Time frame
metabolic parameters	—

Countries

Korea, Republic of

Contacts

Public ContactHae Jin Kim

Ajou University

Outcome results